Breaks Categories: Stock Spotlights

FridayJul 08, 2022 2:54 pm

BioMedNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope, Possible Therapeutic to Alzheimer’s Patients

Silo Pharma (OTCQB: SILO) is committed to serving patients, families and caregivers worldwide struggling with Alzheimer’s Disease (“AD”). Last year, the company entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for AD. Silo Pharma CEO Eric Weisblum expressed encouragement on partnering with Columbia University and Dr. Christine Ann Denny, an associate professor of clinical neurobiology, saying: “To bring hope and possibly a therapeutic to patients suffering from Alzheimer’s Disease is an exciting proposition for Silo Pharma.” Alongside its work with Columbia University, Silo has partnered with Zylo Therapeutics to use Zylo’s Z-pod…

Continue Reading

ThursdayJul 07, 2022 1:24 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Poised to Successfully Commercialize Its Products

Odyssey Health (OTC: ODYY) is a Nevada-based medical company developing a variety of drug and technology assets to treat unmet clinical needs. “Odyssey is dedicated to advancing life-saving medical products that offer similar levels of hope to a new generation of people through technological and clinical developments that demonstrate advantages over current standards of care. At the moment, Odyssey’s market profile includes two medical device candidates and two pharmaceutical products in development. The portfolio is responding to varied needs, including patients who may have undiagnosed heart disease, patients choking on some type of obstruction lodged in their throats, patients dealing…

Continue Reading

FridayJul 01, 2022 1:03 pm

BioMedNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Helping Individuals Make More Informed Decisions

Aditxt (NASDAQ: ADTX) recently partnered with Premier Medical Laboratory Services to provide individuals with personalized information regarding their immune system via the AditxtScore(TM). A recent article reads: “The AditxtScore can be used to provide those tested with important answers to questions like: Are antibodies present? How are these antibodies present – vaccine or natural immune system response? Will this immunity status provide protection from the virus in the future? What is the best approach to creating immunity for that individual?” Regarding the partnership, Kevin Murdock, CEO of Premier Medical Laboratory Services, commented, “As new variants emerge, we want to equip…

Continue Reading

TuesdayJun 28, 2022 3:00 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Pursuing Strategy Against COVID-19, Immune System-Related Maladies

Aditxt (NASDAQ: ADTX) is focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions. “Aditxt is joining the fight against the pandemic while pursuing a larger strategy against immune system-related maladies ranging from seasonal allergies to organ transplant rejection,” a recent article reads. “Aditxt’s first commercial product is an immune monitoring technology trademarked as AditxtScore(TM) for COVID-19, which is designed to provide users with a personalized profile of their immune status – specifically in relation to their vulnerability and immune response regarding COVID’s SARS-CoV-2…

Continue Reading

FridayJun 24, 2022 12:59 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Sets Sights on US Phase II Clinical Trials with Focus on Military

Odyssey Health (OTC: ODYY) understands the severity of concussions among service members as well as the existing gaps in treatment. The Center for Disease Control (“CDC”) reports that over 430,000 military service members were diagnosed with traumatic brain injury (“TBI”) between 2000 and 2020, with 75-83% of the cases being categorized as mild (“mTBI”) or concussion. And though concussion greatly impacts military service members, there is insufficient evidence supporting, among other things, the optimal treatment strategies to mitigate these impacts. “Odyssey Health is working to develop treatments for concussion and other neurological disorders. Odyssey is developing the PRV-002, a novel,…

Continue Reading

WednesdayJun 15, 2022 3:12 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Collaborating to Progress Mission to Create Safe, Effective Therapeutics

Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to progressing Psychedelics to Therapeutics(TM), has joined the ranks of companies dedicated to finding and offering effective solutions to those suffering from mental health conditions. “The company announced that pilot results from its sponsored feasibility study evaluating Flow, Kernel’s quantitative neuroimaging technology, indicate that ketamine-induced changes in the brain’s functional connectivity persisted for several days after receiving the substance,” a recent article reads. “The purpose of the four-week study is to evaluate the altered state of consciousness of an individual following the administration of ketamine. The Kernel Flow headset…

Continue Reading

WednesdayJun 15, 2022 2:20 pm

BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) Novel Drug Candidate Represents a Valuable Asset

Odyssey Health (OTC: ODYY) recently completed a safety evaluation of cohort I of its phase I clinical trial administering PRV-002, the company’s novel drug treatment for concussion. “Findings from the cohort, which included eight healthy human volunteers that received a single dose of PRV-002 or placebo followed by evaluations for abnormal responses, showed that the participants did not exhibit any severe adverse events as PRV-002 was well tolerated,” a recent article reads. “The completion of the safety evaluation is the latest milestone as the company journeys toward providing concussion treatment… With the phase I clinical trial, which consists of 48…

Continue Reading

MondayJun 13, 2022 1:17 pm

BioMedNewsBreaks – Silo Pharma Inc. (SILO) Committed to Psilocybin, Anti-Inflammatory Research

Silo Pharma (OTCQB: SILO) still believes in medicinal mushrooms despite the fact that they are currently outlawed by the U.S. government (though legal in Oregon and decriminalized in various cities and states). Recently, the company announced that the Translational Psychedelic Research (“TrPR”) Program at the University of California San Francisco (“UCSF”) had successfully dosed [with psilocybin] patients who have Parkinson’s disease. “Silo is exploring psilocybin’s anti-inflammatory possibilities in patients exhibiting signs of Parkinson’s,” reads a recent article. “Silo’s commitment to psilocybin and anti-inflammatory research includes: executing an option agreement with the University of Maryland, Baltimore, studying novel system-homing peptides that…

Continue Reading

TuesdayJun 07, 2022 12:51 pm

BioMedNewsBreaks – Why Odyssey Health Inc. (ODYY) Is ‘One to Watch’

Odyssey Health (OTC: ODYY) is a medical technology company focused on developing lifesaving products that offer technological and clinical advantages over current standards of care. Guided by a senior management team with significant experience relating to refining acquired technologies, building commercial systems, and forging strategic partnerships, the company boasts a diverse development portfolio spanning both pharmaceutical candidates and medical devices. “Odyssey has two pharmaceutical products in development: PRV-002 and PRV-001. PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory…

Continue Reading

MondayJun 06, 2022 3:12 pm

BioMedNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Immune Monitoring Platform ‘Is the Right Technology at the Right Time’

Aditxt (NASDAQ: ADTX) recently entered into a multi-year partnership with Guthy-Renker LLC- affiliated GRS. The partnership focuses on building awareness and visibility among consumers and health care providers for the proprietary AditxtScore(TM) Immune Monitoring Platform. “AditxtScore is the right technology at the right time. Our first application, AditxtScore for COVID-19, delivers timely reports on vulnerability and immune status to SARS-CoV-2 and its known variants, giving consumers and their physicians the data they need to make informed health decisions for themselves and their families,” Aditxt CEO and Co-Founder Amro Albanna was quoted in a recent article. Albanna added that the company’s…

Continue Reading